Innovation Articles

1. Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3) 8/5/2026

   Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.

2. Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit 7/24/2026

   At BiotechTV’s U.S. Science Summit, biotech leaders discussed China, AI, scientific storytelling, and what it will take to protect U.S. innovation.

3. Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics 7/22/2026

   Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.

4. Pharmacogenomics In Oncology: A Pharmacokinetic Perspective 7/22/2026

   The outcome of a medical treatment is not solely determined by the efficacy of the drug itself. It also depends on the patient’s genetic makeup, biological characteristics of the disease, and individual clinical factors.

5. From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines 7/21/2026

   Pneumococcal vaccination remains one of the strongest success stories in bacterial disease prevention, but the residual burden is now posing new challenges. 

6. Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3) 7/17/2026

   Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.

7. Can We Cure Diabetes? 7/15/2026

   We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.

8. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

   The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

9. 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio 6/11/2026

   Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.

10. 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics 6/10/2026

    Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.